Search
FSD Pharma Generates $7.7 Million in Proceeds and 670% ROI through Sale of Interest in Cannara Biotech

FSD Pharma Generates $7.7 Million in Proceeds and 670% ROI through Sale of Interest in Cannara Biotech

Author

InvestmentPitchMedia

Published on February 20, 2020

FSD Pharma Inc., a specialty, biotech pharmaceutical R&D company, focused on developing, over time, a robust pipeline of FDA approved synthetic compounds targeting the endocannabinoid system of the human body to treat certain diseases of the central nervous system and autoimmune disorders of the

Show More
Category : News

0 Comments

cmntImg
Auto Play